LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.72 5.98

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.45

Max

3.75

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+16.28% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

162M

1.2B

Ouverture précédente

-2.26

Clôture précédente

3.72

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 déc. 2025, 23:21 UTC

Résultats
Acquisitions, Fusions, Rachats

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 déc. 2025, 23:14 UTC

Acquisitions, Fusions, Rachats

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 déc. 2025, 22:01 UTC

Principaux Mouvements du Marché

Costco Wholesale Reports Higher Monthly Sales

3 déc. 2025, 21:38 UTC

Résultats

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 déc. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 déc. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 déc. 2025, 23:10 UTC

Résultats

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 déc. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 déc. 2025, 23:06 UTC

Acquisitions, Fusions, Rachats

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 déc. 2025, 22:59 UTC

Acquisitions, Fusions, Rachats

EQB to Buy PC Financial From Loblaw for About $573.5M

3 déc. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 déc. 2025, 22:20 UTC

Résultats

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 déc. 2025, 22:19 UTC

Résultats

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 déc. 2025, 22:17 UTC

Résultats

Salesforce Working to Add Voice to Agentforce, CEO Says

3 déc. 2025, 22:16 UTC

Résultats

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 déc. 2025, 22:15 UTC

Résultats

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 déc. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 déc. 2025, 22:09 UTC

Acquisitions, Fusions, Rachats

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 déc. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 déc. 2025, 21:49 UTC

Résultats

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:23 UTC

Résultats

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 déc. 2025, 21:19 UTC

Résultats

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:06 UTC

Résultats

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:04 UTC

Résultats

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 déc. 2025, 21:04 UTC

Résultats

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 déc. 2025, 21:03 UTC

Résultats

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

16.28% hausse

Prévisions sur 12 Mois

Moyen 4 USD  16.28%

Haut 4 USD

Bas 4 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat